Phathom Pharmaceuticals, Inc.
PHAT
$12.56
$0.030.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 58.30M | 57.58M | 49.50M | 39.50M | 28.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.30M | 57.58M | 49.50M | 39.50M | 28.52M |
| Cost of Revenue | 12.00M | 7.65M | 6.19M | 5.04M | 3.72M |
| Gross Profit | 46.31M | 49.94M | 43.31M | 34.47M | 24.80M |
| SG&A Expenses | 54.01M | 48.37M | 51.56M | 85.31M | 94.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.78M | 63.51M | 64.78M | 99.43M | 107.38M |
| Operating Income | -15.48M | -5.93M | -15.27M | -59.92M | -78.86M |
| Income Before Tax | -30.37M | -21.15M | -29.97M | -75.81M | -94.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.37M | -21.15M | -29.97M | -75.81M | -94.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.37M | -21.15M | -29.97M | -75.81M | -94.32M |
| EBIT | -15.48M | -5.93M | -15.27M | -59.92M | -78.86M |
| EBITDA | -15.37M | -5.80M | -15.12M | -59.75M | -78.69M |
| EPS Basic | -0.37 | -0.29 | -0.41 | -1.05 | -1.31 |
| Normalized Basic EPS | -0.23 | -0.18 | -0.26 | -0.65 | -0.82 |
| EPS Diluted | -0.37 | -0.29 | -0.41 | -1.05 | -1.31 |
| Normalized Diluted EPS | -0.23 | -0.18 | -0.26 | -0.65 | -0.82 |
| Average Basic Shares Outstanding | 82.05M | 73.82M | 73.40M | 72.47M | 71.97M |
| Average Diluted Shares Outstanding | 82.05M | 73.82M | 73.40M | 72.47M | 71.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |